The mRNA era is here. MPM believes the future belongs to oRNA — and Big Pharma wants a seat at the table

Amber Tong

If the ultra-fast clinical development of Covid-19 vaccines opened the world’s eyes to the promises of messenger RNA, the subsequent delays in supply offered a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The mRNA era is here. MPM believes the future belongs to oRNA — and Big Pharma wants a seat at the table

Amber Tong

Sign up to read this article for free.

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

The mR­NA era is here. MPM be­lieves the fu­ture be­longs to oR­NA — and Big Phar­ma wants a seat at the ta­ble

Amber Tong

Sign up to read this article for free.

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

The mRNA era is here. MPM believes the future belongs to oRNA — and Big Pharma wants a seat at the table

Senior AstraZeneca exec detained in China amid wider investigation

Pfizer to invest $1B in China over next five years — reports

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks